New pill could replace eye injections for Diabetes-Related vision loss
NCT ID NCT04187443
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an oral drug called MS-553 in 45 people with diabetic macular edema, a condition that causes vision loss in people with diabetes. Participants take the drug daily for 8 weeks. The main goal is to check safety, but researchers will also measure changes in retinal swelling and vision. If safe, larger studies could follow.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MS-553 (oral drug)
What this could lead to
If successful, this could point toward a new oral treatment option for diabetic macular edema, potentially reducing the need for eye injections.
What could go wrong
This is an early Phase 1 trial with only 45 people, focused on safety. It is too small and early to know if the drug will work or be safe long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, 200080, China
Contact
Contact
-
The Second Xiangya Hospital of Central South University
RECRUITINGChangsha, Hunan, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China